Skip to main content
. 2007 Apr 10;66(11):1473–1478. doi: 10.1136/ard.2007.072447

graphic file with name ar72447.f2.jpg

Figure 2 The efficacy of anti‐tumour necrosis factor (TNF) in the active drug group (Active) and the placebo group as the percentages of patients with an ACR20 response compared with the overestimation of the ACR20 response in eligible and ineligible daily clinical practice patients. AD, adalimumab; ET, etanercept; IN, infliximab.